Sobi adding to U.S. presence, hematology pipeline via $915M Dova takeout

With the $915 million takeout of Dova Pharmaceuticals and a co-development deal with Sanofi in hemophilia, Sobi is continuing its push into the U.S. and strengthening its presence in hematology.

Swedish Orphan Biovitrum AB (SSE:SOBI) will acquire Dova Pharmaceuticals Inc. (NASDAQ:DOVA) for $27.50 per share in cash, plus one contingent value right for an additional $1.50 per share upon FDA approval of Dova’s Doptelet avatrombopag to treat chemotherapy-induced thrombocytopenia. The oral thrombopoietin receptor agonist is in a Phase III trial for the indication...